<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diagnosis and management of Cushing syndrome during pregnancy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diagnosis and management of Cushing syndrome during pregnancy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Diagnosis and management of Cushing syndrome during pregnancy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lynnette K Nieman, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">André Lacroix, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles J Lockwood, MD, MHCM</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pregnancy is uncommon in women with Cushing syndrome as hypercortisolism typically results in anovulatory infertility. However, over 260 cases of Cushing syndrome in pregnancy have been reported; these pregnancies are associated with high rates of fetal morbidity and mortality. The diagnosis of Cushing syndrome during pregnancy can be challenging, due to the physiologic changes of the hypothalamic-pituitary-adrenal (HPA) axis during normal pregnancy. Early diagnosis and treatment are essential to reduce maternal and fetal complications.</p><p>This topic will review issues related to Cushing syndrome in pregnancy. The clinical manifestations, diagnosis, and treatment of Cushing syndrome in nonpregnant patients are discussed separately. (See  <a class="medical medical_review" href="/d/html/143.html" rel="external">"Epidemiology and clinical manifestations of Cushing syndrome"</a> and  <a class="medical medical_review" href="/d/html/151.html" rel="external">"Establishing the diagnosis of Cushing syndrome"</a> and  <a class="medical medical_review" href="/d/html/174.html" rel="external">"Overview of the treatment of Cushing syndrome"</a>.)</p><p class="headingAnchor" id="H469687858"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Cushing syndrome is associated with a high prevalence (up to 75 percent) of ovulatory disturbances induced by cortisol excess including amenorrhea and polycystic ovary syndrome [<a href="#rid1">1-4</a>]. As a result, it is uncommon for women with untreated Cushing syndrome to become pregnant [<a href="#rid2">2</a>]. In a systematic review of 168 studies and case reports, 263 pregnancies in 220 women with Cushing syndrome were described; most cases were associated with important maternal and fetal complications [<a href="#rid5">5</a>]. (See <a class="local">'Maternal and fetal complications'</a> below.)</p><p>The majority of cases of Cushing syndrome during pregnancy are in women who are newly diagnosed during the pregnancy, although in the series described [<a href="#rid5">5</a>], 49 of the 263 pregnancies (19 percent), were in women with a diagnosis and <strong>cure</strong> prior to pregnancy.</p><p>The remaining 214 had <strong>active</strong> Cushing syndrome while pregnant. Among the 214 women with active Cushing syndrome, 30 (14 percent) were diagnosed prior to pregnancy, 138 (65 percent) during the pregnancy, and 46 (22 percent) soon after pregnancy (the women diagnosed postpartum presumably had hypercortisolism while pregnant).</p><p class="headingAnchor" id="H1269816579"><span class="h1">CAUSES</span><span class="headingEndMark"> — </span>In nonpregnant women, most cases of Cushing syndrome are due to a corticotropin (ACTH)-secreting pituitary adenoma (Cushing disease), with adrenal adenomas accounting for approximately 15 percent of cases [<a href="#rid6">6</a>]. In contrast, the frequency of ACTH-independent cases is considerably higher in pregnant women with Cushing syndrome. In the systematic review of Cushing syndrome described above, 116 of 213 women (54 percent) with active disease had ACTH-independent Cushing syndrome, primarily adrenal adenomas [<a href="#rid5">5</a>].</p><p>Similar results have been seen in other studies [<a href="#rid1">1,2,6-10</a>]. The reason for this unusual pattern is not known. Pure cortisol-secreting adrenal adenomas may interfere with reproductive function less than the mixed cortisol and androgen excess produced by adrenal carcinomas or ACTH-dependent adrenal hyperplasia. This pattern also may reflect the milder hypercortisolism generally evident with adrenal adenomas, which may lead to less suppression of the hypothalamic-pituitary-ovarian axis.</p><p>Seven pregnant women with the ectopic ACTH syndrome have also been reported [<a href="#rid1">1,5,7,11-13</a>]. (See  <a class="medical medical_review" href="/d/html/125.html" rel="external">"Causes and pathophysiology of Cushing syndrome", section on 'Epidemiology'</a>.)</p><p>In occasional cases, pregnancy appears to induce Cushing syndrome. In a small number of patients, Cushing syndrome remits completely postpartum [<a href="#rid2">2,7,14</a>] and, in a few reported cases, recurs during subsequent pregnancies [<a href="#rid15">15,16</a>]. Possible mechanisms include placental corticotropin-releasing hormone (CRH) production [<a href="#rid17">17</a>], ectopic expression in the adrenal cortex of receptors for luteinizing hormone (LH)/human chorionic gonadotropin (hCG; leading to adrenal adenoma or massive adrenal hyperplasia) [<a href="#rid18">18-21</a>], and estrogen-dependent nodular adrenal hyperplasia [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/d/html/152.html" rel="external">"Cushing syndrome due to primary pigmented nodular adrenocortical disease"</a>.)</p><p>In addition, exacerbation of Cushing syndrome during pregnancy can result from placental-derived ACTH stimulation of ACTH receptors in the adrenal adenoma. In one patient with an adrenal adenoma and modest cortisol secretion, Cushing syndrome became overt during pregnancy and regressed partially after delivery. ACTH receptors, but not aberrant LH/hCG receptors, were identified in the adenoma, suggesting that activation of ACTH receptors in the adrenal adenoma was due to ACTH of placental origin [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H469687864"><span class="h1">HPA CHANGES IN NORMAL PREGNANCY</span><span class="headingEndMark"> — </span>Normal pregnancy is associated with changes in the maternal hypothalamic-pituitary-adrenal (HPA) axis, including increased production of corticosteroid-binding globulin (CBG); increased concentrations of serum, salivary, and urinary free cortisol (UFC); and lack of suppression of serum cortisol after <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>. In addition, the placenta produces corticotropin (ACTH) and corticotropin-releasing hormone (CRH) with the latter's placental expression displaying paradoxical enhancement by glucocorticoid. A further complication is the increase in CRH-binding protein, which may reduce CRH bioavailability [<a href="#rid23">23</a>]. Thus, the biochemical diagnosis of Cushing syndrome during pregnancy is more challenging than in the nonpregnant state.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum cortisol</strong> – Serum total and free cortisol concentrations are increased in pregnant women [<a href="#rid7">7,24</a>]. One study in healthy women reported that plasma cortisol values in pregnancy increased from 14.9±3.4 mcg/dL (411±94 nmol/L) at 12 weeks to 35.2±9.0 mcg/dL (971±248 nmol/L) at 26 weeks gestation and changed minimally thereafter [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Salivary cortisol</strong> – While the bedtime nadir of cortisol is maintained [<a href="#rid7">7</a>], salivary cortisol levels increase during pregnancy. In one study using an enzyme-linked immunosorbent assay (ELISA), the upper limit of normal values were 0.13 mcg/dL (3.6 nmol/L) in nonpregnant control women, 0.25 mcg/dL (6.9 nmol/L) in the first trimester, 0.26 mcg/dL (7.2 nmol/L) in the second trimester, and 0.33 mcg/dL (9.1 nmol/L) in the third trimester [<a href="#rid26">26</a>]. Another study using radioimmunoassay found elevated midnight salivary cortisol values in 18 women during the second and third trimesters (2.41±1.33 ng/mL, range 0.68 to 6.80) compared with 89 control women (1.37±0.57 ng/mL, range 0.16 to 3.0) [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urinary cortisol</strong> – Urine cortisol also increases during pregnancy. One study using radioimmunoassay found a two- to threefold increase in UFC in the second and third trimesters, compared with nonpregnant women [<a href="#rid7">7</a>]. A second study using liquid chromatography/mass spectrometry compared values in each trimester (first trimester 135±10 nmol/d, second trimester 187±13 nmol/d, third trimester 242±15 nmol/d) with those of nonpregnant women (78±12 nmol/d) [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Plasma ACTH</strong> – Plasma ACTH concentrations are slightly lower than those of nonpregnant women during early pregnancy but gradually increase to slightly above normal; in one report, ACTH values using radioimmunoassay were 23±4.6 pg/mL at twelve weeks, with a progressive increase to 59±16 pg/mL at 37 weeks [<a href="#rid25">25</a>]. The increase in ACTH is due at least in part to placental ACTH secretion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dexamethasone</strong><strong> suppression testing</strong> – Suppression of cortisol by <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> is blunted during pregnancy, particularly in the second and third trimesters. In one report, the percent reduction of morning serum cortisol levels after dexamethasone (1 mg administered at 11 PM) was 87 percent in nonpregnant control women, compared with pregnant women who had lower degrees of suppression: 83, 44, and 37 percent in the first, second, and third trimesters, respectively [<a href="#rid28">28</a>].</p><p></p><p class="headingAnchor" id="H3098971655"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H174773151"><span class="h2">Overlap with features of pregnancy</span><span class="headingEndMark"> — </span>The clinical features of Cushing syndrome during pregnancy (weight gain, fatigue, hypertension) overlap with many of the signs and symptoms that women without Cushing syndrome may experience during pregnancy [<a href="#rid1">1</a>].</p><p>Cushing syndrome is often not detected until the second trimester, possibly because the potential signs and symptoms of Cushing syndrome are attributed to pregnancy rather than Cushing syndrome [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H511303062"><span class="h2">Biochemical findings</span><span class="headingEndMark"> — </span>In the series of 136 pregnant women with Cushing syndrome described above [<a href="#rid6">6</a>], mean corticotropin (ACTH) concentrations were considerably higher in women with Cushing disease than in women with adrenal adenomas [<a href="#rid6">6</a>]. These results are discussed below. (See <a class="local">'Additional evaluation to determine cause'</a> below.)</p><p class="headingAnchor" id="H511303241"><span class="h2">Imaging</span><span class="headingEndMark"> — </span>In the same study, among those with Cushing disease, only 13 of 18 had adequate imaging; 6 of 13 had macroadenomas, a higher percentage than is evident in nonpregnant patients [<a href="#rid6">6</a>]. Detailed imaging data were not available from the systematic review described above [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H4083698728"><span class="h2">Maternal and fetal complications</span><span class="headingEndMark"> — </span>The fetus is partially protected from the hypercortisolemia because placental 11-beta-hydroxysteroid dehydrogenase type 2 converts 85 percent of maternal cortisol to biologically inactive cortisone [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/d/html/2284.html" rel="external">"Placental development and physiology", section on 'Steroid hormones'</a>.)</p><p>However, maternal and neonatal complications occur commonly [<a href="#rid5">5</a>]. In a review of 136 pregnant women with Cushing syndrome (78 with no treatment and 107 live births), maternal complications included [<a href="#rid6">6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Gestational diabetes or impaired glucose tolerance – 25 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension – 68 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Preeclampsia – 14 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Heart failure – 3 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Psychiatric disorders – 4 percent</p><p></p><p>Two maternal deaths have also been reported [<a href="#rid1">1</a>].</p><p>In the same series of 136 cases including 107 live births, neonatal complications included [<a href="#rid6">6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Intrauterine deaths/spontaneous abortions – 5 percent, n = 6 (other series report have reported higher rates [<a href="#rid30">30</a>])</p><p class="bulletIndent1"><span class="glyph">●</span>Premature delivery – 43 percent, n = 46</p><p class="bulletIndent1"><span class="glyph">●</span>Intrauterine growth retardation – 21 percent, n = 22</p><p class="bulletIndent1"><span class="glyph">●</span>Still births – 6 percent, n = 8</p><p class="bulletIndent1"><span class="glyph">●</span>Neonatal adrenal insufficiency – 2 percent, n = 2</p><p></p><p>A separate series including 214 (128 with no treatment) cases of women with active Cushing syndrome demonstrated an overall fetal loss rate of 24 percent (48 of 214 pregnancies). Other outcomes included high rates of intrauterine fetal death and spontaneous abortion (17 percent), and premature delivery (66 percent) [<a href="#rid5">5</a>]. Women who received treatment had lower rates of fetal loss as described in the next section.</p><p class="headingAnchor" id="H3"><span class="h1">DIAGNOSIS DURING PREGNANCY</span></p><p class="headingAnchor" id="H3749049696"><span class="h2">Initial testing</span><span class="headingEndMark"> — </span>The evaluation and diagnosis of suspected Cushing syndrome in pregnancy differs from that for nonpregnant patients [<a href="#rid31">31</a>]. Unfortunately, there are no pregnancy-specific guidelines for interpretation of these tests, but we use both the urinary free cortisol (UFC) and late-night salivary cortisol tests [<a href="#rid26">26,27</a>]. We do <strong>not</strong> use the <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> suppression test to diagnose Cushing syndrome during pregnancy, because of the risk for false-positive results [<a href="#rid10">10</a>]. (See <a class="local">'HPA changes in normal pregnancy'</a> above.)</p><p>We consider the diagnosis of Cushing syndrome in pregnancy to be established when:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>UFC</strong> – UFC is more than four times the upper limit of normal (for nonpregnant women) <strong>or </strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Late-night salivary cortisol</strong> –<strong> </strong>Late-night salivary cortisol is three to four times above the upper limit of normal (for nonpregnant women) [<a href="#rid24">24</a>]. </p><p></p><p class="bulletIndent1">The lack of well-established reference ranges for these tests in normal pregnancy renders diagnosis less clear in milder cases [<a href="#rid24">24,27</a>]. The diagnosis of Cushing syndrome in pregnancy is also challenging because Cushing syndrome can easily masquerade as gestational diabetes or hypertension during pregnancy. (See  <a class="medical medical_review" href="/d/html/151.html" rel="external">"Establishing the diagnosis of Cushing syndrome"</a>.)</p><p></p><p>For any given salivary cortisol assay, values obtained in the second to third trimester of more than three to four times the normal reference range appear to support the diagnosis of Cushing syndrome. Measurement of bedtime or midnight plasma or salivary cortisol are commonly used tests to establish hypercortisolism in nonpregnant patients. Midnight salivary cortisol is significantly increased in normal pregnant women compared with nonpregnant controls, but can be distinguished from most patients with Cushing disease [<a href="#rid26">26,27</a>].</p><p>One study that used enzyme-linked immunosorbent assay (ELISA) to set late-night salivary cortisol reference ranges in pregnancy found that median values in pregnant women without Cushing syndrome were twice those of nonpregnant healthy controls. Individual values overlapped with those seen in nonpregnant Cushing syndrome patients [<a href="#rid26">26</a>]. Another study using radioimmunoassay found that midnight salivary cortisol values in normal pregnant women (1.6 to 9.13 ng/mL) overlapped with those seen in nonpregnant Cushing syndrome patients (3.88 to 49.1 ng/mL) [<a href="#rid27">27</a>]. Additional studies are needed using other assay platforms to determine appropriate reference ranges in pregnancy.</p><p class="headingAnchor" id="H4"><span class="h2">Additional evaluation to determine cause</span><span class="headingEndMark"> — </span>Initial biochemical testing to determine etiology is directed to identifying adrenal causes of Cushing syndrome, which are more common in pregnancy. This strategy also defers more risky testing (corticotropin-releasing hormone [CRH], which is no longer available, magnetic resonance imaging [MRI], inferior petrosal sinus sampling [IPSS]).</p><p>Measurement of corticotropin (ACTH) and the high-dose <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> suppression test provide complementary information:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dexamethasone</strong><strong> suppression tests</strong> – As noted, we do not use the 1 mg overnight <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> test to make the diagnosis of hypercortisolism during pregnancy. However, a high-dose (8 mg) dexamethasone suppression test (see <a class="local">'Biochemical findings'</a> above) is sometimes performed to help determine etiology.</p><p></p><p class="bulletIndent1">There are limited data on the responses of serum cortisol to <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (8 mg) in pregnant women with adrenal causes of Cushing syndrome and pituitary adenomas. In a review of 136 women with Cushing syndrome during pregnancy, 14 women underwent an overnight 8 mg or two-day, high-dose dexamethasone suppression test. (See  <a class="medical medical_review" href="/d/html/156.html" rel="external">"Establishing the cause of Cushing syndrome", section on 'High-dose dexamethasone suppression tests'</a>.)</p><p></p><p class="bulletIndent1">Using a criterion of 80 percent or greater suppression of serum or urinary cortisol to identify Cushing disease, all patients with ACTH-independent Cushing syndrome were correctly identified but three of seven with Cushing disease failed to suppress [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/d/html/160.html" rel="external">"Dexamethasone suppression tests", section on 'High-dose DSTs'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ACTH levels</strong> – Because of the persistent elevations of ACTH in normal pregnancy, a suppressed ACTH is not always found in primary adrenal causes of Cushing syndrome. In the series of 136 pregnant women with Cushing syndrome described above [<a href="#rid6">6</a>], mean ACTH concentrations for the different categories of Cushing syndrome were:</p><p></p><p class="bulletIndent1">Cushing disease (n = 18) 69.4±25.9 pg/mL (15.3±5.7 pmol/L)</p><p></p><p class="bulletIndent1">Adrenal adenoma (n = 13) 32.5±17.6 pg/mL (7.2±3.9 pmol/L); 5 of 13 women had undetectable ACTH (ie, &lt;10 pg/mL)</p><p></p><p class="bulletIndent1">These values were obtained at various times in pregnancy, using older radioimmunoassay techniques, as well as more modern "sandwich" immunoassays. As a result, there may be significant overlap between the expected value in normal pregnancy, unless the values are higher (indicating Cushing disease) or lower (indicating adrenal adenoma).</p><p></p><p class="bulletIndent1">Patients without suppression after high-dose <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> and a borderline or low ACTH (&lt;10 pg/mL [4.4 pmol/L]) are likely to have an adrenal etiology. Ultrasound-identified adrenal lesions were present in 73 percent of cases in the series described [<a href="#rid6">6</a>]. If the adrenal ultrasound is negative, we suggest an adrenal MRI without a contrast agent, but <strong>not</strong> in the first trimester, because of concerns about potential adverse fetal effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other testing</strong> – Higher ACTH levels (&gt;10 pg/mL [4.4 pmol/L]), or suppression after <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> suggest Cushing disease. There are few data on the utility of the CRH or <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> stimulation tests or pituitary MRI. MRI can eventually be performed, but not in the first trimester, because of concerns about potential adverse fetal effects; during the remainder of gestation, it may be performed, but<strong> not</strong> with gadolinium contrast, which is labeled by the US Food and Drug Administration (FDA) as a class C drug. Performing MRI during pregnancy without gadolinium contrast reduces its sensitivity (from approximately 50 to 38 percent) [<a href="#rid32">32</a>]. In one study, it detected a pituitary adenoma in five of eight patients with Cushing disease, including three macroadenomas [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1">CRH stimulation and IPSS have been reported in less than 10 pregnant patients [<a href="#rid6">6</a>]. If IPSS is done, access via the jugular vein, with abdominal and chest lead shielding, is recommended to reduce radiation exposure to the fetus during fluoroscopy. (See <a class="local">'ACTH-dependent Cushing syndrome'</a> below.)</p><p></p><p class="headingAnchor" id="H5"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The goal in women with Cushing syndrome diagnosed prior to pregnancy should <strong>always</strong> be treatment and a cure before proceeding with attempts to conceive. We suggest that all pregnant women with Cushing syndrome be followed by both a maternal-fetal medicine specialist and an endocrinologist with experience in the diagnosis and treatment of Cushing syndrome.</p><p>Medical therapy and surgical intervention both reduce the<em> </em>risk of fetal loss significantly, although the high rates of preterm<em> </em>birth and low birth weight do not appear to improve<em> </em>[<a href="#rid5">5,6</a>]. The choice of medical or surgical therapy is individualized and depends upon the cause of the patient's Cushing syndrome. Women in whom an adrenal adenoma or pituitary adenoma have been clearly identified may undergo surgical resection in the second trimester. Medical treatment options are also available.</p><p class="headingAnchor" id="H540620754"><span class="h2">Timing of treatment</span><span class="headingEndMark"> — </span>Women with Cushing syndrome during pregnancy should be treated as early as possible, ideally before 20 weeks gestation. It has been difficult to evaluate the true impact of therapy because it has been typically instituted relatively late in pregnancy (because most women are not diagnosed until the second trimester). (See <a class="local">'Clinical features'</a> above.)</p><p>In the series of 136 pregnant women with Cushing syndrome described above [<a href="#rid6">6</a>], the live birth rate appeared to be slightly better in women who received early treatment compared with those who were managed conservatively; 50 live births out of 56 pregnancies (89 percent) if treatment started at a mean gestational age of 20 weeks, versus 59 live births out of 74 pregnancies (76 percent) in the group receiving no therapy in the third trimester [<a href="#rid6">6</a>]. In the series of 214 patients, those who received no treatment had a higher overall fetal loss (31 percent) than those receiving medical (21 percent) or surgical (13 percent) treatment [<a href="#rid5">5</a>]. However, complications, including premature delivery and eclampsia, occurred in some women in spite of treatment.</p><p class="headingAnchor" id="H540620710"><span class="h2">ACTH-independent Cushing syndrome</span><span class="headingEndMark"> — </span>As noted above, approximately 60 percent of pregnant women with Cushing syndrome have corticotropin (ACTH)-independent Cushing syndrome (45 percent adrenal adenoma and 15 percent adrenal carcinoma). Adrenal surgery has been performed at 16 to 21 weeks of pregnancy without complicating the pregnancy [<a href="#rid1">1,7</a>].</p><p class="headingAnchor" id="H2666190579"><span class="h3">Adrenal surgery</span><span class="headingEndMark"> — </span>For pregnant women with ACTH-independent Cushing syndrome, we suggest the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Surgical tumor resection appears to be more uniformly successful than medical therapy [<a href="#rid5">5</a>]. Therefore, for most women, we suggest early second trimester adrenal surgery. (See  <a class="medical medical_review" href="/d/html/15027.html" rel="external">"Adrenalectomy techniques"</a> and  <a class="medical medical_review" href="/d/html/174.html" rel="external">"Overview of the treatment of Cushing syndrome"</a>.)</p><p></p><p class="headingAnchor" id="H4228861026"><span class="h3">Medical therapy</span></p><p class="bulletIndent1"><span class="glyph">●</span>For women who do not want surgery or are diagnosed later, we suggest <a class="drug drug_general" data-topicid="10156" href="/d/drug information/10156.html" rel="external">metyrapone</a>, given every six to eight hours, at a dose sufficient to reduce maternal hypercortisolism into the normal pregnancy range [<a href="#rid7">7,33</a>]. It may become necessary to induce early delivery of the fetus if complications of eclampsia supervene [<a href="#rid7">7,15,34</a>]. (See  <a class="medical medical_review" href="/d/html/119.html" rel="external">"Medical therapy of hypercortisolism (Cushing's syndrome)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other therapeutic options for ACTH-independent disease are associated with potential problems (see  <a class="medical medical_review" href="/d/html/119.html" rel="external">"Medical therapy of hypercortisolism (Cushing's syndrome)"</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">Ketoconazole</a> is teratogenic and toxic to animal embryos but has been used successfully and without harm to fetuses from as early as the seventh week of pregnancy [<a href="#rid35">35,36</a>]. Similar to <a class="drug drug_general" data-topicid="10156" href="/d/drug information/10156.html" rel="external">metyrapone</a>, it is given every six to eight hours, at a dose sufficient to reduce maternal hypercortisolism into the normal pregnancy range. Because of the potential for feminization of a male fetus and maternal hepatotoxicity, we suggest that its use be reserved for those who need emergency medical therapy but cannot tolerate metyrapone.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9659" href="/d/drug information/9659.html" rel="external">Mitotane</a> should <strong>not</strong> be given to pregnant women, as it crosses the placenta and is teratogenic [<a href="#rid37">37</a>]. However, it was used in one woman without complications [<a href="#rid38">38</a>].</p><p></p><p class="headingAnchor" id="H540620704"><span class="h2">ACTH-dependent Cushing syndrome</span></p><p class="headingAnchor" id="H1868021973"><span class="h3">Surgery or medical therapy</span><span class="headingEndMark"> — </span>For pregnant women with Cushing disease, transsphenoidal surgery (ideally early in the second trimester) <strong>or</strong> medical therapy (generally with <a class="drug drug_general" data-topicid="10156" href="/d/drug information/10156.html" rel="external">metyrapone</a>) have both been used [<a href="#rid1">1,5,6,39,40</a>].</p><p>At one institution, four pregnant women with Cushing disease underwent transsphenoidal surgery; remission was achieved in three women, but fetal/neonatal deaths occurred in two pregnancies [<a href="#rid6">6</a>]. One intrauterine death due to a tight nuchal cord, occurred at 33 weeks in a woman with persistent Cushing disease postoperatively. The second occurred after early delivery (24 weeks) for reversal of cord blood flow in a woman who had remission of her hypercortisolism postoperatively but persistent hypertension and eventual toxemia. (See  <a class="medical medical_review" href="/d/html/86683.html" rel="external">"Transsphenoidal surgery for pituitary adenomas and other sellar masses"</a>.)</p><p class="headingAnchor" id="H2634348983"><span class="h2">Management of comorbidities</span><span class="headingEndMark"> — </span>In addition to specific treatment of Cushing syndrome, women should receive additional treatment related to any comorbidities, such as diabetes and hypertension, both of which are common in this population [<a href="#rid5">5,6</a>]. Patients should be counselled about the potential for premature labor. Definitive treatment should be initiated postpartum.</p><p class="headingAnchor" id="H1775980799"><span class="h2">Glucocorticoids during labor and delivery</span><span class="headingEndMark"> — </span>Women who achieve surgical remission during pregnancy should receive <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> sufficient to achieve trimester-specific levels of urine cortisol. At the time of labor and delivery, they should be treated as if they have adrenal insufficiency. After delivery, the hydrocortisone dose should be gradually decreased over three months as corticosteroid-binding globulin (CBG) decreases [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/d/html/155.html" rel="external">"Treatment of adrenal insufficiency in adults", section on 'Pregnancy and labor'</a>.)</p><p>If women are receiving steroidogenesis inhibitors, they should be discontinued (or reduced) when labor begins to allow for increased cortisol production and should be restarted at a lower dose following delivery. (See  <a class="medical medical_review" href="/d/html/119.html" rel="external">"Medical therapy of hypercortisolism (Cushing's syndrome)"</a>.)</p><p class="headingAnchor" id="H540620698"><span class="h2">Outcomes</span><span class="headingEndMark"> — </span>Treating Cushing syndrome during pregnancy reduces maternal morbidity and fetal mortality. However, it does not appear to reduce the frequency of intrauterine growth restriction (approximately 30 percent) or preterm birth [<a href="#rid5">5,6,10,30,41,42</a>].</p><p>One review reported an improvement in live birth rates with treatment (59 live births in 74 pregnant women who did not receive therapy [76 percent] and 50 live births in 56 pregnant women who did receive treatment [89 percent]) [<a href="#rid6">6</a>]. In the systematic review of 213 cases of women with active Cushing syndrome during pregnancy, fetal loss occurred in 30 of 128 women (31 percent) who were untreated, compared with 5 of 24 (21 percent) who received medical therapy (most often <a class="drug drug_general" data-topicid="10156" href="/d/drug information/10156.html" rel="external">metyrapone</a>) and 6 of 49 (13 percent) who underwent surgery (transsphenoidal surgery or adrenalectomy [unilateral in most cases]) [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H1549564378"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112709.html" rel="external">"Society guideline links: Diagnosis and treatment of Cushing syndrome"</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Pregnancy is uncommon in women with Cushing syndrome as hypercortisolism typically results in anovulatory infertility. Other clinical features of Cushing syndrome during pregnancy, including weight gain, fatigue, and hypertension, overlap with many of the signs and symptoms that women without Cushing syndrome may experience during pregnancy. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes</strong> – Of those who do become pregnant, approximately 55 percent have corticotropin (ACTH)-independent hypercortisolism (primarily adrenal adenomas). This pattern is different from that seen in nonpregnant individuals with Cushing syndrome, the majority of whom have ACTH-dependent hypercortisolism (ACTH-secreting pituitary tumors). (See <a class="local">'Causes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial testing</strong> – The evaluation of suspected Cushing syndrome in pregnancy differs from that in nonpregnant patients. We suggest combined use of urinary free cortisol (UFC) and late-night salivary cortisol, although there are no pregnancy-specific guidelines for interpretation of these tests. (See <a class="local">'Initial testing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diagnostic criteria</strong> – We consider the diagnosis of Cushing syndrome in pregnancy to be established when UFC is more than <strong>four</strong> times the upper limit of normal (for nonpregnant women) or when salivary cortisol is <strong>three to four</strong> times above the upper limit of normal (for nonpregnant women). (See <a class="local">'Diagnosis during pregnancy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Evaluation to determine cause</strong> – We perform a high-dose (8 mg) <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> suppression test and measure ACTH to help determine the etiology. (See <a class="local">'Additional evaluation to determine cause'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>ACTH independent</strong> – We suggest surgical resection of adrenal adenomas causing Cushing syndrome during pregnancy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). This is typically performed at 16 to 21 weeks of pregnancy without complicating the pregnancy. (See <a class="local">'Management'</a> above and  <a class="medical medical_review" href="/d/html/174.html" rel="external">"Overview of the treatment of Cushing syndrome", section on 'Unilateral adrenalectomy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>ACTH dependent</strong> – For women with a well-established diagnosis of Cushing disease, we suggest transsphenoidal surgery (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>), ideally in the second trimester. (See <a class="local">'ACTH-dependent Cushing syndrome'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Women who decline or are not candidates for surgery</strong> – For women who do not want surgery or are diagnosed later, we suggest <a class="drug drug_general" data-topicid="10156" href="/d/drug information/10156.html" rel="external">metyrapone</a> to control maternal hypercortisolism (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). It may become necessary to induce early delivery of the fetus if complications of eclampsia supervene. (See <a class="local">'Management'</a> above and  <a class="medical medical_review" href="/d/html/119.html" rel="external">"Medical therapy of hypercortisolism (Cushing's syndrome)", section on 'Metyrapone'</a>.)</p><p></p><p class="headingAnchor" id="H1954444075"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The views expressed in this topic are those of the author(s) and do not reflect the official views or policy of the United States Government or its components.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Aron DC, Schnall AM, Sheeler LR. Cushing's syndrome and pregnancy. Am J Obstet Gynecol 1990; 162:244.</a></li><li><a class="nounderline abstract_t">Buescher MA, McClamrock HD, Adashi EY. Cushing syndrome in pregnancy. Obstet Gynecol 1992; 79:130.</a></li><li><a class="nounderline abstract_t">Lado-Abeal J, Rodriguez-Arnao J, Newell-Price JD, et al. Menstrual abnormalities in women with Cushing's disease are correlated with hypercortisolemia rather than raised circulating androgen levels. J Clin Endocrinol Metab 1998; 83:3083.</a></li><li><a class="nounderline abstract_t">Kaltsas GA, Korbonits M, Isidori AM, et al. How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome? Clin Endocrinol (Oxf) 2000; 53:493.</a></li><li><a class="nounderline abstract_t">Caimari F, Valassi E, Garbayo P, et al. Cushing's syndrome and pregnancy outcomes: a systematic review of published cases. Endocrine 2017; 55:555.</a></li><li><a class="nounderline abstract_t">Lindsay JR, Jonklaas J, Oldfield EH, Nieman LK. Cushing's syndrome during pregnancy: personal experience and review of the literature. J Clin Endocrinol Metab 2005; 90:3077.</a></li><li><a class="nounderline abstract_t">Buescher, MA. Cushing's syndrome in pregnancy. Endocrinologist 1996; 6:357.</a></li><li><a class="nounderline abstract_t">Caticha O, Odell WD, Wilson DE, et al. Estradiol stimulates cortisol production by adrenal cells in estrogen-dependent primary adrenocortical nodular dysplasia. J Clin Endocrinol Metab 1993; 77:494.</a></li><li><a class="nounderline abstract_t">Spaniol A, Mulla BM, Daily JG, Ennen CS. Carney complex: a rare cause of Cushing syndrome in pregnancy. Obstet Gynecol 2014; 124:426.</a></li><li><a class="nounderline abstract_t">Machado MC, Fragoso MCBV, Bronstein MD. Pregnancy in Patients with Cushing's Syndrome. Endocrinol Metab Clin North Am 2018; 47:441.</a></li><li><a class="nounderline abstract_t">Guilhaume B, Sanson ML, Billaud L, et al. Cushing's syndrome and pregnancy: aetiologies and prognosis in twenty-two patients. Eur J Med 1992; 1:83.</a></li><li><a class="nounderline abstract_t">Hadden DR. Adrenal disorders of pregnancy. Endocrinol Metab Clin North Am 1995; 24:139.</a></li><li><a class="nounderline abstract_t">Cohade C, Broussaud S, Louiset E, et al. Ectopic Cushing's syndrome due to a pheochromocytoma: a new case in the post-partum and review of literature. Gynecol Endocrinol 2009; 25:624.</a></li><li><a class="nounderline abstract_t">Close CF, Mann MC, Watts JF, Taylor KG. ACTH-independent Cushing's syndrome in pregnancy with spontaneous resolution after delivery: control of the hypercortisolism with metyrapone. Clin Endocrinol (Oxf) 1993; 39:375.</a></li><li><a class="nounderline abstract_t">Hána V, Dokoupilová M, Marek J, Plavka R. Recurrent ACTH-independent Cushing's syndrome in multiple pregnancies and its treatment with metyrapone. Clin Endocrinol (Oxf) 2001; 54:277.</a></li><li><a class="nounderline abstract_t">Achong N, D'Emden M, Fagermo N, Mortimer R. Pregnancy-induced Cushing's syndrome in recurrent pregnancies: case report and literature review. Aust N Z J Obstet Gynaecol 2012; 52:96.</a></li><li><a class="nounderline abstract_t">Jones SA, Brooks AN, Challis JR. Steroids modulate corticotropin-releasing hormone production in human fetal membranes and placenta. J Clin Endocrinol Metab 1989; 68:825.</a></li><li><a class="nounderline abstract_t">Lacroix A, Ndiaye N, Tremblay J, Hamet P. Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome. Endocr Rev 2001; 22:75.</a></li><li><a class="nounderline abstract_t">Wy LA, Carlson HE, Kane P, et al. Pregnancy-associated Cushing's syndrome secondary to a luteinizing hormone/human chorionic gonadotropin receptor-positive adrenal carcinoma. Gynecol Endocrinol 2002; 16:413.</a></li><li><a class="nounderline abstract_t">Plöckinger U, Chrusciel M, Doroszko M, et al. Functional Implications of LH/hCG Receptors in Pregnancy-Induced Cushing Syndrome. J Endocr Soc 2017; 1:57.</a></li><li><a class="nounderline abstract_t">Andreescu CE, Alwani RA, Hofland J, et al. Adrenal Cushing's syndrome during pregnancy. Eur J Endocrinol 2017; 177:K13.</a></li><li><a class="nounderline abstract_t">St-Jean M, MacKenzie-Feder J, Bourdeau I, Lacroix A. Exacerbation of Cushing's syndrome during pregnancy: stimulation of a cortisol-secreting adrenocortical adenoma by ACTH originating from the foeto-placental unit. Endocrinol Diabetes Metab Case Rep 2019; 2019.</a></li><li><a class="nounderline abstract_t">Grammatopoulos DK. Placental corticotrophin-releasing hormone and its receptors in human pregnancy and labour: still a scientific enigma. J Neuroendocrinol 2008; 20:432.</a></li><li><a class="nounderline abstract_t">Jung C, Ho JT, Torpy DJ, et al. A longitudinal study of plasma and urinary cortisol in pregnancy and postpartum. J Clin Endocrinol Metab 2011; 96:1533.</a></li><li><a class="nounderline abstract_t">Carr BR, Parker CR Jr, Madden JD, et al. Maternal plasma adrenocorticotropin and cortisol relationships throughout human pregnancy. Am J Obstet Gynecol 1981; 139:416.</a></li><li><a class="nounderline abstract_t">Lopes LM, Francisco RP, Galletta MA, Bronstein MD. Determination of nighttime salivary cortisol during pregnancy: comparison with values in non-pregnancy and Cushing's disease. Pituitary 2016; 19:30.</a></li><li><a class="nounderline abstract_t">Manetti L, Rossi G, Grasso L, et al. Usefulness of salivary cortisol in the diagnosis of hypercortisolism: comparison with serum and urinary cortisol. Eur J Endocrinol 2013; 168:315.</a></li><li><a class="nounderline abstract_t">Odagiri E, Ishiwatari N, Abe Y, et al. Hypercortisolism and the resistance to dexamethasone suppression during gestation. Endocrinol Jpn 1988; 35:685.</a></li><li><a class="nounderline abstract_t">Lindsay JR, Nieman LK. The hypothalamic-pituitary-adrenal axis in pregnancy: challenges in disease detection and treatment. Endocr Rev 2005; 26:775.</a></li><li><a class="nounderline abstract_t">Caimari F, Corcoy R, Webb SM. Cushing's disease: major difficulties in diagnosis and management during pregnancy. Minerva Endocrinol 2018; 43:435.</a></li><li><a class="nounderline abstract_t">Hamblin R, Coulden A, Fountas A, Karavitaki N. The diagnosis and management of Cushing's syndrome in pregnancy. J Neuroendocrinol 2022; 34:e13118.</a></li><li><a class="nounderline abstract_t">Tabarin A, Laurent F, Catargi B, et al. Comparative evaluation of conventional and dynamic magnetic resonance imaging of the pituitary gland for the diagnosis of Cushing's disease. Clin Endocrinol (Oxf) 1998; 49:293.</a></li><li><a class="nounderline abstract_t">Blanco C, Maqueda E, Rubio JA, Rodriguez A. Cushing's syndrome during pregnancy secondary to adrenal adenoma: metyrapone treatment and laparoscopic adrenalectomy. J Endocrinol Invest 2006; 29:164.</a></li><li><a class="nounderline abstract_t">Orth DN, Liddle GW. Results of treatment in 108 patients with Cushing's syndrome. N Engl J Med 1971; 285:243.</a></li><li><a class="nounderline abstract_t">Amado JA, Pesquera C, Gonzalez EM, et al. Successful treatment with ketoconazole of Cushing's syndrome in pregnancy. Postgrad Med J 1990; 66:221.</a></li><li><a class="nounderline abstract_t">Berwaerts J, Verhelst J, Mahler C, Abs R. Cushing's syndrome in pregnancy treated by ketoconazole: case report and review of the literature. Gynecol Endocrinol 1999; 13:175.</a></li><li><a class="nounderline abstract_t">Leiba S, Weinstein R, Shindel B, et al. The protracted effect of o,p'-DDD in Cushing's disease and its impact on adrenal morphogenesis of young human embryo. Ann Endocrinol (Paris) 1989; 50:49.</a></li><li><a class="nounderline abstract_t">Knappe G, Gerl H, Ventz M, Rohde W. [The long-term therapy of hypothalamic-hypophyseal Cushing's syndrome with mitotane (o,p'-DDD)]. Dtsch Med Wochenschr 1997; 122:882.</a></li><li><a class="nounderline abstract_t">Casson IF, Davis JC, Jeffreys RV, et al. Successful management of Cushing's disease during pregnancy by transsphenoidal adenectomy. Clin Endocrinol (Oxf) 1987; 27:423.</a></li><li><a class="nounderline abstract_t">Kriplani A, Buckshee K, Ammini AC. Cushing syndrome complicating pregnancy. Aust N Z J Obstet Gynaecol 1993; 33:428.</a></li><li><a class="nounderline abstract_t">Bronstein MD, Machado MC, Fragoso MC. MANAGEMENT OF ENDOCRINE DISEASE: Management of pregnant patients with Cushing's syndrome. Eur J Endocrinol 2015; 173:R85.</a></li><li><a class="nounderline abstract_t">Kyriakos G, Farmaki P, Voutyritsa E, et al. Cushing's syndrome in pregnancy: a review of reported cases. Endokrynol Pol 2021; 72:64.</a></li></ol></div><div id="topicVersionRevision">Topic 139 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2405679" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cushing's syndrome and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1727571" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cushing syndrome in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9745407" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Menstrual abnormalities in women with Cushing's disease are correlated with hypercortisolemia rather than raised circulating androgen levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11012575" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27704478" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cushing's syndrome and pregnancy outcomes: a systematic review of published cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15705919" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cushing's syndrome during pregnancy: personal experience and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cushing's syndrome in pregnancy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8345057" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Estradiol stimulates cortisol production by adrenal cells in estrogen-dependent primary adrenocortical nodular dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25004313" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Carney complex: a rare cause of Cushing syndrome in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29754643" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pregnancy in Patients with Cushing's Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1342378" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cushing's syndrome and pregnancy: aetiologies and prognosis in twenty-two patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7781622" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Adrenal disorders of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19591016" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Ectopic Cushing's syndrome due to a pheochromocytoma: a new case in the post-partum and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8222300" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : ACTH-independent Cushing's syndrome in pregnancy with spontaneous resolution after delivery: control of the hypercortisolism with metyrapone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11207645" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Recurrent ACTH-independent Cushing's syndrome in multiple pregnancies and its treatment with metyrapone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22188308" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pregnancy-induced Cushing's syndrome in recurrent pregnancies: case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2537843" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Steroids modulate corticotropin-releasing hormone production in human fetal membranes and placenta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11159817" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12587537" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pregnancy-associated Cushing's syndrome secondary to a luteinizing hormone/human chorionic gonadotropin receptor-positive adrenal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29264446" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Functional Implications of LH/hCG Receptors in Pregnancy-Induced Cushing Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28819015" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Adrenal Cushing's syndrome during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30738017" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Exacerbation of Cushing's syndrome during pregnancy: stimulation of a cortisol-secreting adrenocortical adenoma by ACTH originating from the foeto-placental unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18266947" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Placental corticotrophin-releasing hormone and its receptors in human pregnancy and labour: still a scientific enigma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21367926" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A longitudinal study of plasma and urinary cortisol in pregnancy and postpartum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6258436" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Maternal plasma adrenocorticotropin and cortisol relationships throughout human pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26346684" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Determination of nighttime salivary cortisol during pregnancy: comparison with values in non-pregnancy and Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23211575" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Usefulness of salivary cortisol in the diagnosis of hypercortisolism: comparison with serum and urinary cortisol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3220047" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Hypercortisolism and the resistance to dexamethasone suppression during gestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15827110" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The hypothalamic-pituitary-adrenal axis in pregnancy: challenges in disease detection and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29442480" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Cushing's disease: major difficulties in diagnosis and management during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35491087" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The diagnosis and management of Cushing's syndrome in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9861318" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Comparative evaluation of conventional and dynamic magnetic resonance imaging of the pituitary gland for the diagnosis of Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16610244" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Cushing's syndrome during pregnancy secondary to adrenal adenoma: metyrapone treatment and laparoscopic adrenalectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4326256" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Results of treatment in 108 patients with Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2362890" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Successful treatment with ketoconazole of Cushing's syndrome in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10451809" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Cushing's syndrome in pregnancy treated by ketoconazole: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2729882" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The protracted effect of o,p'-DDD in Cushing's disease and its impact on adrenal morphogenesis of young human embryo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9264918" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : [The long-term therapy of hypothalamic-hypophyseal Cushing's syndrome with mitotane (o,p'-DDD)].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3325196" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Successful management of Cushing's disease during pregnancy by transsphenoidal adenectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8179562" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Cushing syndrome complicating pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25872515" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : MANAGEMENT OF ENDOCRINE DISEASE: Management of pregnant patients with Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33749819" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cushing's syndrome in pregnancy: a review of reported cases.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
